SCHEMBL6211850

SCHEMBL6211850

Fc1cccc(CNc2nc(Cl)ncc2Br)c1F

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 5/20 0.42
▸ AURKA O14965 1/20 0.41
▸ PDPK1 O15530 1/20 0.41
▸ RPS6KB1 P23443 1/20 0.41
▸ P2RX7 Q99572 1/20 0.40
▸ CDK1 P06493 1/20 0.39
▸ MEN1 O00255 3/20 0.39
▸ ALDH1A1 P00352 2/20 0.39
▸ L3MBTL1 Q9Y468 2/20 0.39
▸ ABL1 P00519 1/20 0.38
▸ BCR P11274 1/20 0.38
▸ PRKCQ Q04759 1/20 0.37
▸ STAT6 P42226 1/20 0.37
▸ ADORA3 P0DMS8 1/20 0.36
▸ ADORA1 P30542 1/20 0.36
▸ NTRK1 P04629 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ PKM P14618 1/20 0.36
▸ KDM4E B2RXH2 1/20 0.35
▸ CYP1A2 P05177 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6209176 0.89 MEN1 (0.47) KMT2AAURKARPS6KB1CDK1MEN1
SCHEMBL5912776 0.85 ALDH1A1 (0.41) KMT2ACDK1MEN1ALDH1A1L3MBTL1
SCHEMBL22261236 0.79 AURKA (0.58) AURKAPDPK1RPS6KB1STAT6
SCHEMBL6209980 0.79 GAA (0.43) KMT2AAURKARPS6KB1MEN1ALDH1A1
SCHEMBL6833106 0.79 CCND3 (0.42) KMT2AMEN1ALDH1A1L3MBTL1ABL1
SCHEMBL6213937 0.79 P2RX7 (0.43) KMT2AP2RX7CDK1MEN1ALDH1A1
SCHEMBL2032760 0.76 L3MBTL1 (0.54) KMT2AAURKARPS6KB1MEN1ALDH1A1
SCHEMBL6213223 0.75 ATM (0.54) KMT2AMEN1ALDH1A1NTRK1MAPT
SCHEMBL6211911 0.75 HDAC3 (0.51) KMT2AP2RX7MEN1ALDH1A1PRKCQ
SCHEMBL6212214 0.75 PDE5A (0.55) KMT2ACDK1MEN1ALDH1A1NTRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1578732-A2 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH Pfizer Products Inc. (US) 2005-09-28 — — EP disclosed
US-20040220177-A1 Compound for the treatment of abnormal cell growth PFIZER INC 2004-11-04 — — US disclosed
WO-2004056786-A2 PYRIMIDINE DERIVATES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER PRODUCTS INC. (US) 2004-07-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220177-A1 Compound for the treatment of abnormal cell growth CCNA1, CCNB1, CCNT1 KMT2A 2928/4885AURKA 731/4885PDPK1 2780/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback